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Background and Objectives: Our objective was to identify differentially expressed
genes involved in the pathogenesis of glioblastoma multiforme (GBM).
Methods: Screening of arrayed human fetal brain and human postnatal brain cDNA
libraries was performed by differential hybridization with glioblastoma multiforme
and human normal brain cDNAs.
Results: Repeated differential hybridization of more than 100 cDNA clones selected
by primary screening and analysis of RNA from adult normal brain and glial tumors
showed 16 nucleotide sequences differentially expressed between normal brain and
brain tumors. Among others, decreased content in astrocytic tumors was determined
for TSC-22 mRNA corresponding to cDNA in the ICRFp507J1041 clone from human
fetal brain cDNA library. Northern blot hybridization of RNA from different human
brain tumors showed very low amounts of TSC-22 mRNA in most investigated
samples of GBM, anaplastic astrocytoma, and some other tumors. Complete lack of
expression of TSC-22 occurred in one sample of anaplastic astrocytoma, as well as in
meningioma, brain sarcoma, sarcomatous meningioma, and oligodendroglioma. The
differential expression of TSC-22 gene was confirmed by semiquantitative RT-PCR in
15 samples of astrocytomas WHO grade II–IV and three samples of normal brain.
Conclusions: Significantly decreased levels of TSC-22 mRNA in human brain and
salivary gland tumors and antiproliferative role of TSC-22 strongly suggest a tumor
suppressor role for TSC-22.
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INTRODUCTION
The current picture of the molecular basis of human
brain tumors presents a complex interplay between mul-
tiple genetic events involving nonrandom chromosomal
anomalies, activation of protooncogenes, inactivation of
tumor suppressor genes, and the aberrant expression of
growth factors and their receptors. Epidermal growth
factor receptor (EGFR), as well as platelet-derived growth
factor (PDGF) and its receptors, have been characterized
as contributing oncogenes. Several investigative groups
have provided cytogenetic and molecular genetic evi-
dence for the existence of unidentified putative tumor
suppressor genes on chromosomal arms 1p, 9p, 10q, 11p,
13q, 17p, 19q, and 22q, in addition to known tumor
suppressor genes [1–7].
However, present knowledge recognizes only a frac-
tion of the biological mechanisms assumed to initiate and
promote brain tumor formation. The candidate gene
approach, correlating common genetic alterations found
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in human brain tumors with outcome or response to
treatment, has yielded contradictory results. A more
comprehensive approach is to include gene expression in
the analysis in order not only to concentrate on structural
alterations, but also to encompass regulatory differences.
Identification and characterization of novel molecular
markers or genes either induced or repressed in human
brain tumors will contribute to understanding the mecha-
nisms of tumor initiation and progression. Better know-
ledge of such mechanisms is likely to improve diagnostic
and prognostic evaluation, and is necessary to define
biological targets for the design of comprehensive thera-
peutic approaches. Predictive markers would be extre-
mely helpful in identifying patients who would benefit
from specific treatments.
In this work, the TSC-22 gene (transforming growth
factor-b [TGF-b1]-stimulated clone 22), originally iden-
tified as a primary response gene [8], was found to have a
significantly decreased level of the expression in some
human brain tumors, as compared with that in normal
brain. The present work describes the results in accor-
dance with previously published data, indicating a poten-
tial tumor suppressor role of the TSC-22 gene.
MATERIALS AND METHODS
Human Tissues and cDNA Libraries
Brain tumor and normal tissues were procured from
tumor tissue bank maintained by the Romodanov
Institute of Neurosurgery, Kiev, Ukraine. Of 27 tumors
used in this work, 23 were primary tumors, and 4 were
recurrent tumors. One patient with a primary tumor
received chemotherapy before surgical excision. Surgical
specimens of human fetal brain were supplied by Center
of Embryonic Tissues, Kiev. High-density cDNA filter
arrays of human fetal and infant brain cDNA libraries
came from The Resource Center/Primary Database
(RZPD) of the German Human Genome Project (Max
Planck Institute for Molecular Genetics, Berlin and
Deutsches Krebsforschungszentrum, Heidelberg).
Differential Hybridization of cDNA Libraries
Differential hybridization of 32P-labeled human glio-
blastoma and normal brain cDNAs to gridded human
brain cDNA libraries was performed as described in our
previous articles [9–11]. Total cDNA probes for dif-
ferential hybridization were synthesized on the total
RNAs, isolated from surgical specimens of human
normal brain and primary astrocytic tumors: glioblastoma
multiforme (GBM) and anaplastic astrocytoma. The con-
ditions of oligo(dT)-primed cDNA synthesis were as des-
cribed in standard procedure [12], but the concentration
of dCTP was reduced to 25 mM, and 150–200 mCi of
[a-32P]dCTP was added to the reaction to obtain cDNA
probes with high specific activity. cDNA filter arrays
were consequentially hybridized with tumor and nor-
mal brain cDNA probes and the coordinates of cDNA
clones with altered hybridization signals between tumor
and control cDNAs were determined on the gridded
arrays. The clones were requested from RZPD (http://
www.rzpd.de); repeated differential hybridization of
these clones was carried out.
RNA Isolation
Total RNA was isolated from liquid nitrogen–frozen
surgical specimens of human brain tumors and normal tis-
sues, as well as from samples of normal fetal human brain
by acid guanidinium thyiocyanate-phenol-chlorophorm
extraction [13]. (Surgical specimens of histologically
normal brain tissue adjacent to tumor were used as a
source for normal adult human brain RNA.)
Northern Blot Analysis
Total RNA (20 mg per lane) was separated electro-
phoretically in 1.5% agarose gel containing 2.2 M
formaldehyde and was then transferred to a Hybond-N
nylon membrane (Amersham Pharmacia Biotech). The
membrane was hybridized with a 32P-labeled human
TSC-22 cDNA probe (106 cpm/ml) in 50% formamide;
5 SSC; 5Denhardt’s solution; 0.1% sodium dodecyl
sulfate (SDS), and 100 mg/ml salmon sperm DNA at 428C
overnight. Extensive washing was performed: twice with
2 SSC, 0.1% SDS for 15 min at room temperature; once
with 2 saline sodium citrate (SSC), 0.1% SDS for
30 min at 658C; and finally with 0.2SSC, 0.1% SDS for
30 min at 658C. Subsequently, the membrane was ex-
posed to radiographic film with an intensifying screen at
708C. The membrane was rehybridized sequentially
with a 32P-labeled human b-actin cDNA probe as a con-
trol of gel loading. Densitometric analysis of signals was
performed by Scion Image 1.62c program.
Southern Blot Analysis
Genomic DNA from human astrocytic tumors and
from blood samples of tumor patients and unrelated
individuals was isolated by phenol/chloroform extrac-
tion [12], digested with HindIII endonuclease, separat-
ed by electrophoresis in 0.6% agarose gel in 1TBE
buffer, and transferred onto a Hybond-N nylon mem-
brane (Amersham Pharmacia Biotech). The membrane
was hybridized with a 32P-labeled human TSC-22
cDNA (106 cpm/ml) in 50% formamide; 5SSC; 5
Denhardt’s solution; 0.1% SDS and 100 mg/ml salmon
sperm DNA at 428C overnight. Washing conditions:
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twice with 2 SSC, 0.1% SDS for 30 min at room
temperature; once with 2SSC, 0.1% SDS for 30 min at
658C; and finally with 0.2 SSC, 0.1% SDS for 30 min at
658C. The filter was exposed to radiographic film with an
intensifying screen at 708C.
Semiquantitative RT-PCR
Semiquantitative reverse transcription-polymerase chain
reaction (RT-PCR) with TSC-22-specific primers was
performed on normal brain and brain tumor RNA
samples as described by Rae et al. [14]. Equal amounts
of total cellular RNA (10 mg each) were reverse trans-
cribed into cDNA with an oligo(dT) primer. In a 20-ml
reaction, PCR was performed with cDNA synthesized
from 0.5 mg of total RNA, 2 U Taq-polymerase, 1 PCR
buffer, 0.2 mM dNTPs, and 1mM TSC-22-specific pri-
mers. Thermal cycling parameters were 948C for 30 s,
568C for 1 min, and 728C for 1 min for 30 cycles, fol-
lowed by a further 7 min at 728C. The number of cycles
was then decreased until the PCR product amplifica-
tion rate was in the linear phase (27 cycles). Amplified
products were electrophoresed in a 2% agarose gel and
transferred to a nylon membrane. The membrane was
subsequently hybridized with a 32P-labeled TSC-22
cDNA probe (106 cpm/ml) in 50% formamide to detect
very low quantities of TSC-22 mRNA in some tumor
samples.
Nucleotide Sequence Analysis
Nucleotide sequences of cDNA inserts were determin-
ed according to the Sanger method [15]. The GenBank
and EMBL databases were searched for overall nucleic
acid homologies by the BLAST program via the Internet.
RESULTS
Identification of the Genes Differentially Expressed
Between Normal Brain and Brain Tumors
As with subtractive hybridization techniques [16], dif-
ferential hybridization is advantageous in that it does
not require a priori sequence information, but it is uni-
que in that both commonly and specifically expressed
mRNAs in multiple tissues or cell samples can be com-
pared simultaneously. Thus, in the same experiment,
genes expressed only in normal tissues (e.g., tumor
suppressor genes), as well as genes that are tumor speci-
fic (e.g., tumor markers, activated oncogenes), can be
identified [17].
Differential hybridization of arrayed human fetal
brain and human postnatal brain cDNA libraries with
total cDNA probes of GBM and normal adult brain
showed more than 100 cDNA clones with differences
in the intensity of hybridization. Repeated differential
hybridization of cDNA clones, selected by primary scre-
ening, and nucleotide sequence analysis of cDNA inserts
allowed us to identify 16 nucleotide sequences whose
expression has been changed by 3–10-fold (for several
cases, by more than 10-fold) in tumor cells. The infor-
mation about these sequences is shown in Table I. The
potential tumor-specific expression of isolated nucleo-
tide sequences was verified by Northern blotting, using
membranes with total RNA from brain tumors and
control tissues. The total length and splice patterns of
transcripts in normal human tissues and in astrocytomas
of different malignancy grades were evaluated. Because
of the problem presented by heterogeneous expression
among individual tumors and among normal brain sam-
ples, different normal brain samples and astrocytoma
tissues were subjected to comparative analysis.
TSC-22 mRNA was identified among the sequences
with decreased content in the GBM. The nucleotide
sequence of TSC-22 cDNA from human fetal brain
cDNA clone ICRFp507J1041 is shown in Figure 1 (found
under Accession No. AJ222700 in the databases). The
nucleotide sequence of ICRFp507J1041 cDNA is iden-
tical to previously published TSC-22 cDNA nucleotide
sequence [18,19] but due to the alternative processing
of the 30-untranslated region the ICRFp507J1041 cDNA
is two nucleotides shorter than the published TSC-22
cDNA. The heterogeneity of polyadenylation sites gen-
erated under the influence of a single polyadenylation
signal was described by us previously for transcripts from
three different genes in human fetal liver [20].
Decreased Expression of TSC-22
Gene in Brain Tumors
Northern blot hybridization was carried out in order to
examine the level and size of the TSC-22 gene transcript
in individual human brain tumors (Fig. 2). Four different
samples of histologically normal adult brain, adjacent to
the tumor and ablated due to necessity in the course of
surgery, were used as a source of RNA for comparison of
gene expression in normal brain. The radiolabeled TSC-
22 cDNA hybridized to a major band of RNA of 1.8-kb
size in normal tissues, e.g., heart and kidney (lanes 1 and
2) and adult normal brain (lanes 3–6). However, amounts
of the 1.8-kb mRNA were varied in the tumor tissues
tested. Comparison of the hybridization signals with the
TSC-22 cDNA probe clearly showed a significant de-
crease in TSC-22 mRNA contents in three of four GBM
samples (lanes 8–10). There was also a decreased level of
the TSC-22 mRNA in the fourth GBM (lane 7). A very
low level of TSC-22 mRNAwas detected in three of five
anaplastic astrocytomas (lanes 11, 14, 18). Gene expres-
sion level was also decreased in three World Health
Organization (WHO) grade II astrocytomas (lanes 13,
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20, 21), although to a lesser extent than in GBMs and
anaplastic astrocytomas. A very low level of TSC-22
mRNA was also observed in one benign meningioma
(lane 17). It was not detectable at all in some other types
of malignant tumors, i.e., meningioma sarcomatous,
brain sarcoma, andWHO grade II–III oligodendroglioma
(lanes 22, 23, and 24, correspondingly).
Subsequent semiquantitative RT-PCR analysis was
performed for verification of differential expression of
TSC-22 gene between normal brain and astrocytic
tumors. RT-PCR analysis confirmed the results obtained
by Northern hybridization and demonstrated decreased
expression in astrocytomas grade II and III and absence
of the expression of TSC-22 in all 8 samples of GBM
analyzed (Fig. 3).
TSC-22 Gene Locus Does Not Have Deletions
in Astrocytic Tumors
Southern blot hybridization of genomic DNA from
astrocytomas of different malignancy grades and from
blood samples of tumor patients and unrelated individuals
was performed to examine possible deletions at the TSC-
22 gene locus. HindIII-digested DNAwas hybridized to a
32P-labeled fragment of ICRFp507J1041 cDNA, synthe-
sized by PCR, using primers pr1 and pr2 (positions of
the primers are indicated in Fig. 1). This analysis did not
show differences in the hybridization pictures of tumor
DNA (Fig. 4), or of blood DNA from tumor patients and
nontumor DNA of unrelated individuals. Two hybridiz-
ed 4.7- and 2.2-kb fragments were shown in all DNA
samples. The presence of a 4.7-kb fragment is in ac-
cordance with the genomic sequence of the TSC-22 gene
(Accession No. AL138960). An additional 2.2-kb frag-
ment may represent the gene from another allele.
DISCUSSION
In the present study, we have identified the TSC-22
gene—one of the genes characterized by differential
hybridization as differentially expressed between normal
human brain and human brain tumors. We found that
expression of this gene was significantly decreased in
astrocytomas of different malignancy grades and in some
other types of brain tumors.
The TSC-22 gene belongs to the family of early
response genes and was originally isolated from
mouse osteoblastoma cDNA library as a gene that was
stimulated by transforming growth factor-b1 (TGF b1-
stimulated clone 22) [8]. Its expression grows rapidly in
response to cell treatment by bacterial lipopolysac-
charides (LPS), some cytokines (TGF-b1, tumor nec-
rosis factor-a [TNF-a], and interferon-g [IFN-g]) [19],
and other inductors (dexamethasone, cholera toxin, and
phorbol 12-myristate 13-acetate [PMA]) [8]. TSC-22 was
shown to be one of the target genes for progesterone [21].
Induction by progesterone suggests the presence of the
progesterone response element in the TSC-22 gene
TABLE I. Nucleotide Sequences Differentially Expressed Between Human Adult Normal Brain and
Astrocytic Gliomas
Clones Identity/highest homology Expression in glioblastoma
ICRFp507M243 mt 16S iRNA Increased
ICRFp507H2345 mt 16S rRNA Increased
COLUp553J0232 mt 16S rRNA Increased
COLUp553J2484 mt 16S rRNA Increased
COLUp553I0714 mt 12S rRNA Increased
COLUp553P2336 mt 12S rRNA Increased
ICRFp507G1815, 28S rRNA Increased
COLUp553C1116 28S rRNA Increased
ICRFp507I0511 Apolipoprotein E Increased
ICRFp507B2047 DNA binding protein B Increased
ICRFp507F0246 TRAF6-like protein (contains Alu repeat) Increased
ICRFp507G2490 Human homologue to hypothetical C. Caenorhabditis
elegans 9.8-kDa protein
Increased
ICRFp507C1134 Novel (contains Alu repeat) Increased
ICRFp507F0552 Novel (contains Alu repeat) Increased
ICRFp507M1080 Novel (contains Alu repeat) Increased
ICRFp507J2448 MLL septin-like fusion protein Increased
ICRFp507G124 FX protein Decreased
ICRFp507J1041 TSC-22 Decreased
ICRFp507L1033 Cullin 1 Decreased
ICRFp507C063 Novel, chromosome 13 Decreased
ICRFp507O073 Novel, chromosome 2 Decreased
60 Shostak et al.
promoter. The growth of the expression of the TSC-22
gene in the response to dexamethasone, a synthetic acti-
vator of the glucocorticoid receptor [8], supports this
suggestion.
TSC-22 contains a leucine zipper motif. It has been
hypothesized as a transcription factor [8], although it
does not contain a classic DNA-binding domain such
as those in the bZip or bHLH-Zip families. TSC-22 was
determined to be the transcription regulator of the C-type
natriuretic peptide gene, interacting with GC-rich ele-
ments of its promoter [19]. Recent studies showed trans-
cription repressor activity of TSC-22, which can form
Fig. 1. Nucleotide sequence of TSC-22 cDNA from clone ICRFp507J1041 and predicted amino acid sequence of TSC-22 protein. The amino
acid sequence is presented in the single-letter code, above the first positions of the codons. Four leucine and one valine residue, which form
putative leucine zipper structure, and polyadenylation signal are underlined. Positions of polymerase chain reaction (PCR) primers (pr1, pr2, pr3,
and pr4) are indicated with arrows.
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homodimers via its leucine zipper domain [22]. It is
possible that TSC-22 may form heterodimers with
basic leucine zipper transcription factors and that it
may repress classical transcription activators as a domi-
nant negative regulator, such as helix-loop-helix proteins
Id1–Id4 [23].
Decreased content, and even complete absence, of
TSC-22 mRNAwere also found in benign and malignant
human salivary gland tumors, as compared with that in
the normal salivary gland [24]. In contrast, TSC-22 dis-
played a negative regulatory effect on cell proliferation.
Fig. 2. Expression of TSC-22 mRNA in normal human tissues and in brain tumors. A: Northern blot hybridization of 32P-labeled
ICRFp507J1041 cDNA probe with total RNA from: lane 1, adult heart; lane 2, adult kidney; lanes 3–6, samples of adult normal brain;
lanes 7–10, samples of GBM; lanes 11,12,14,15,18, samples of anaplastic astrocytoma; lane 16, fetal brain (6 weeks old); lanes 13, 20, 21,
samples of astrocytoma (WHO grade II); lane 17, benign meningioma; lane 19, anaplastic meningioma; lane 22, meningioma sarcomatous;
lane 23, brain sarcoma; lane 24, oligodendroglioma (WHO grade II–III). B: Bar graph showing relative expression of TSC-22 gene after
correction for gel loading based on b-actin gene expression.
Fig. 3. Semiquantitative RT-PCR for TSC-22 mRNA. PCR was
carried out with primers pr3 and pr4 indicated in Fig. 1. PCR with
primers to b-actin gene was used as a control for cDNA synthesis.
TSC-22 PCR products were hybridized subsequently with 32P-labeled
ICRFp507J1041 cDNA probe. Lanes 1–3, samples of adult normal
brain; lanes 4,5, samples of astrocytoma (WHO grade II); lanes
6–10, samples of anaplastic astrocytoma; lanes 11–18, samples of
GBM.
Fig. 4. Southern analysis of TSC-22 gene in DNA from tumor
samples. Southern blot was hybridized with 32P-labeled fragment of
ICRFp507J1041 cDNA, synthesized by PCR with primers pr1 and pr2
indicated in Fig. 1. Each lane contains 10 mg of HindIII-digested DNA
from: lanes 1–3,5,8, GBMs; lanes 4,6,7, anaplastic astrocytomas;
lane 9, normal brain; lane 10, oligodendroastrocytoma. Positions of
fragments of DNA size marker (MassRuler DNA Ladder, Mix,
Fermentas) are shown on the right side.
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The investigation of apoptotic cell death mechanism
in the human gastric carcinoma cell line HSC-39 after
treatment with TGF-b1 showed that TSC-22 can play
the role of the mediator of TGF-b1 signaling pathway to
apoptosis [25]. HSC-39 cells transfected with a TSC-
22–expressing vector showed a significant decrease in
cell viability and elicited apoptotic cell death through
the activation of CPP32-like protease because the syn-
thetic peptide inhibitor, specific to CPP32-type protease,
protected the cells against death. Treatment of human
salivary gland cancer cell line TYS under quiescent con-
ditions by antisense oligonucleotide against TSC-22
mRNA stimulated the growth of TYS cells; however,
under growing conditions, the antisense oligonucleotide
did not affect cell growth [26]. Furthermore, the anti-
proliferative effect of anticancer drug vesnarinone was
suppressed by the antisense oligonucleotide. These results
also indicate that TSC-22 may be a negative regulator of
cell growth and that it may play an important role in
the antiproliferative effect of vesnarinone. Upregula-
tion of the TSC-22 protein affected neither in vitro nor
in vivo growth of TYS cells, but downregulation of
TSC-22 markedly enhanced their growth in vitro and
in vivo [24].
The TSC-22 gene was mapped to chromosome 13 at
position q14 [18]. The location of this gene on the
chromosome 13 may be determined more precisely by
the NCBI Map Viewer. The TSC-22 gene has been
localized in the 13q13.2–13q13.3 region. The loss of the
chromosome arm 13q occurs in up to 50% of human
astrocytomas, suggesting the presence of astrocytoma
tumor suppressor gene(s) at that location [27–30]. Loss
of heterozygosity (LOH) at the retinoblastoma (Rb) sus-
ceptibility gene locus, located on 13q14, was detected
in 30% of high-grade astrocytomas, but was not detect-
ed in low-grade gliomas [27]. These results indicate
that the Rb gene locus is targeted by the deletions in
13q, but they also suggest the possibility of the presence
of other astrocytoma suppressor gene(s) in this region—
and TSC-22 gene may be one of them. We performed
Southern blot hybridization of genomic DNA from astro-
cytomas of different malignancy grades and from blood
samples of tumor patients and unrelated healthy indi-
viduals, to examine possible deletions at the TSC-22
gene locus in astrocytic gliomas. However, Southern blot
analysis did not demonstrate the differences in hybri-
dization patterns of tumor and nontumor DNA. It may
be concluded that the repression of TSC-22 gene acti-
vity in tumor cells may be caused by changes in its
regulation.
Thus, the significantly decreased content of TSC-22
mRNA in human brain and salivary gland tumors and
the negative role of TSC-22 protein in cell proliferation
suggest the possible tumor suppressor role of this gene.
Recent studies showed that the constructions ex-
pressing TSC-22 may be useful in the chemotherapy of
tumors. Overexpression of TSC-22 markedly enhanced
chemosensitivity of human salivary gland cancer cells
in vitro and in vivo via 5-fluorouracil-induced apoptosis
[31,32].
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